Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
International Symposium on Ghrelin and Energy Metabolism Homeostasis
Ghrelin does not influence cancer progression in a lung adenocarcinoma cell line
Hironobu TsubouchiHitomi OnomuraYusuke SaitoShigehisa YanagiAyako MiuraAyako MatsuoNobuhiro MatsumotoMasamitsu Nakazato
著者情報
ジャーナル フリー

2017 年 64 巻 Suppl. 号 p. S41-S46

詳細
抄録

Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor (GHSR), is produced in the human stomach. Although ghrelin has therapeutic potential for cancer cachexia, ghrelin treatment may have a concern about accelerating cancer progression. Here, using the human lung adenocarcinoma cell line HLC-1, we investigated the effects of ghrelin on molecular mechanisms linked to cancer progression, including cell viability, proliferation, resistance to apoptosis, and mitochondrial activity. Both types of mouse alveolar epithelial cells (types I and II) expressed the GHSR, as did the human normal airway cell lines BEAS-2B and HLC-1. Treatment with ghrelin (10-2, 10-1, 1, 10 μM) did not affect cell viability or proliferation. Pretreatment of HLC-1 cells with ghrelin (10 μM) did not affect resistance to paclitaxel-induced apoptosis. The parameters of mitochondrial respiration, including basal respiration, proton leak, ATP production, maximal respiration, spare respiratory capacity, and non-mitochondrial respiration, of the HLC-1 cells pretreated with or without ghrelin were unchanged. Taken together, ghrelin does not influence cancer progression in lung adenocarcinoma cells.

著者関連情報
© The Japan Endocrine Society
前の記事 次の記事
feedback
Top